Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

Strategic Management to Optimize Response To Cardiac Resynchronization Therapy

NCT03089281 · View on ClinicalTrials.gov ↗

Study Summary

The primary objective is to evaluate the benefit of the SmartDelay™ algorithm in patients with a prolonged RV-LV interval.

Conditions Studied

Interventions

  • DEVICE CRT-D

Study Locations (20)

Florida

  • Baptist Health Research Institute — Jacksonville
  • Watson Clinic Center for Research, Inc — Lakeland
  • Winter Haven Hospital — Winter Haven

Alabama

  • Affinity Hospital, LLC d/b/a Granview Medical Center — Birmingham
  • Heart Center Research LLC — Huntsville

California

  • Glendale Adventist Medical Center — Glendale
  • Salinas Valley Memorial Healthcare System — Salinas

Georgia

  • Emory University Hospital — Atlanta
  • Northside Hospital — Atlanta

Illinois

  • The University of Chicago — Chicago
  • St. John's Hospital — Springfield

Kentucky

  • St. Elizabeth Healthcare — Edgewood
  • Baptist Health Lexington — Lexington

Massachusetts

  • Lahey Hospital and Medical Center — Burlington
  • Southcoast Health — Fall River

Arizona

  • University of Arizona Sarver Heart Center — Tucson

Trial Details

FieldValue
Enrollment Target 699 participants
Start Date 2017-08-01
Est. Completion 2020-09-15
Phase NA

Sponsor

Boston Scientific Corporation

120 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03089281

The ClinicalTrials.gov registry entry for NCT03089281 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 699 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 120 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention — of which CRT-D is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03089281 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, Alabama, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03089281 about?

NCT03089281 is a clinical study titled "Strategic Management to Optimize Response To Cardiac Resynchronization Therapy". The primary objective is to evaluate the benefit of the SmartDelay™ algorithm in patients with a prolonged RV-LV interval.

What is the current status of trial NCT03089281?

This trial is currently completed. It is a NA study. The enrollment target is 699 participants. The study started on 2017-08-01. Estimated completion is 2020-09-15.

What conditions does trial NCT03089281 study?

This clinical trial studies the following conditions: Heart Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03089281?

The interventions under investigation include: CRT-D (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03089281?

This trial is sponsored by Boston Scientific Corporation, which has 120 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03089281 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial